Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.78
Quick Ratio3.35
Price-To-Earnings
Trailing P/E Ratio-75.66
Forward P/E Ratio-39.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$482.25 million
Price / Sales21.70
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book14.04
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-34.51%
Return on Equity-29.74%
Return on Assets-23.94%
Miscellaneous
Employees1,100
Outstanding Shares158,220,000
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics, Inc. (NASDAQ:SGEN) issued its earnings results on Thursday, April, 26th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.31. The biotechnology company earned $140.59 million during the quarter, compared to analyst estimates of $119.04 million. Seattle Genetics had a negative return on equity of 29.74% and a negative net margin of 34.51%. The company's quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.42) earnings per share. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What price target have analysts set for SGEN?
17 brokerages have issued 12-month target prices for Seattle Genetics' stock. Their predictions range from $48.00 to $80.00. On average, they anticipate Seattle Genetics' stock price to reach $65.1429 in the next twelve months. View Analyst Ratings for Seattle Genetics.
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. HC Wainwright analysts commented, "We believe the FDA warning against CPI usage in the first-line setting last month, and the long DOR by CPI treatment in the second-line setting presented at ASCO this weekend, may result in a delay in EV-201 trial enrollment and primary study completion initially planned in 2020. Last month, the FDA issued a warning against single-agent checkpoint inhibition for frontline PDL1-low patients, based on a recent data monitoring committee (DMC) assessment for the phase 3 KEYNOTE-361 study (pembrolizumab, Merck, MRK; not rated) and the phase 3 IMvigor130 study (atezolizumab, Genentech, DNA; not rated) results." (6/5/2018)
- 2. Cann analysts commented, "We have not included any sales or earnings from enfortumab vedotin by 2022 due to its stage of development, but we are encouraged by its development program, including data in the ASCO abstract and its having received Breakthrough Therapy Designation. Genetics’ approved drug for Hodgkin’s lymphoma, had sales of $307.6 million, or 63.8% of total revenue, in 2017. We estimate that Adcetris sales, including additional indications, CTCL and Anaplastic large cell lymphoma, and label expansion into frontline Hodgkin’s lymphoma, will increase to $766.7 million in 2022 and account for 70% of revenue. Continued strong data from ECHELON-1 are expected to drive adoption in the frontline Hodgkin’s setting." (5/17/2018)
- 3. According to Zacks Investment Research, "Seattle Genetics' dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. However, efforts to expand Adcetris’s label is encouraging. The label expansion in pcALCL, CD30-expressing MF and T-cell lymphoma will boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. Meanwhile, the company’s shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of Q1 results. Seattle Genetics has a mixed record of earnings surprises in the recent quarters." (4/23/2018)
- 4. JPMorgan Chase & Co. analysts commented, "Forecasts; We Expect Shares to Be Pressured Monday morning, ViewRay announced preliminary 2017 revenue of $34M and 4Q17 orders of $34M. Both metrics were significantly below our expectations. With so much investor focus on system sales and conversion to revenue, we expect VRAY to trade off today. The company recognized revenue on 4 MRIdian Linac Systems in the quarter. For the full year, VRAY announced total revenue of $34M. We had modeled $42.5M in revenue for the full year. Management noted that revenue recognition was delayed on one of the 5 systems shipped or installed in the quarter. That delay should result in $7M in revenue recognized in a later period. Investors have been eager to see backlog convert to revenue and this miss is likely to disappoint. In the quarter, VRAY received $34M in new MRIdian Linac System orders, less than the $48M we had forecasted. That order number is lower the company’s orders in the second quarter and likely does not demonstrate enough of an uptick in momentum from the $29.9M order reported in 3Q." (1/9/2018)
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Aerie Pharmaceuticals (AERI), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Repligen (RGEN).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
- Mr. Todd E. Simpson, Chief Financial Officer (Age 57)
- Dr. Vaughn B. Himes, Chief Technology Officer (Age 57)
- Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)
- Dr. Jonathan G. Drachman, Strategic Advisor for Innovation (Age 56)
Has Seattle Genetics been receiving favorable news coverage?
Press coverage about SGEN stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Seattle Genetics earned a media sentiment score of 0.08 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.11 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Seattle Genetics' major shareholders?
Seattle Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BAKER BROS. ADVISORS LP (32.10%), Baillie Gifford & Co. (9.27%), BlackRock Inc. (5.37%), Manning & Napier Group LLC (1.48%), Wasatch Advisors Inc. (0.62%) and Pinnacle Associates Ltd. (0.57%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Which institutional investors are selling Seattle Genetics stock?
SGEN stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Legal & General Group Plc, Manning & Napier Group LLC, Pinnacle Associates Ltd., Russell Investments Group Ltd., Swiss National Bank, Opus Point Partners Management LLC and Great West Life Assurance Co. Can. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Which institutional investors are buying Seattle Genetics stock?
SGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Wells Fargo & Company MN, UBS Group AG, Bedell Frazier Investment Counseling LLC, Summit Trail Advisors LLC, JPMorgan Chase & Co. and Millennium Management LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Bros Advisors Lp Baker and Felix Baker. View Insider Buying and Selling for Seattle Genetics.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $66.55.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $10.58 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
